1. Cinnamoyl Sucrose Esters as Alpha Glucosidase Inhibitors for the Treatment of Diabetes.
- Author
-
Devaraj S, Yip YM, Panda P, Ong LL, Wong PWK, Zhang D, and Judeh Z
- Subjects
- Animals, Cinnamates chemistry, Computer Simulation, Glycoside Hydrolase Inhibitors chemistry, Humans, Molecular Docking Simulation, alpha-Amylases antagonists & inhibitors, Cinnamates pharmacology, Diabetes Mellitus drug therapy, Esters chemistry, Glycoside Hydrolase Inhibitors pharmacology, Sucrose chemistry, alpha-Glucosidases chemistry
- Abstract
Cinnamoyl sucrose esters (CSEs) were evaluated as AGIs and their enzyme inhibition activity and potency were compared with gold standard acarbose. The inhibition activity of the CSEs against α-glucosidase and α-amylase depended on their structure including the number of the cinnamoyl moieties, their position, and the presence or absence of the acetyl moieties. The inhibitory values of the CSEs 2 - 9 generally increases in the order of mono-cinnamoyl moieties < di-cinnamoyl ≤ tri-cinnamoyl < tetra-cinnamoyl. This trend was supported from both in vitro and in silico results. Both tetra-cinnamoyl CSEs 5 and 9 showed the highest α-glucosidase inhibitory activities of 77 ± 5%, 74 ± 9%, respectively, against acarbose at 27 ± 4%, and highest α-amylase inhibitory activities of 98 ± 2%, 99 ± 1%, respectively, against acarbose at 93 ± 2%. CSEs 3 , 4 , 6 , 7 , 8 showed desired higher inhibition of α-glucosidase than α-amylase suggesting potential for further development as AGIs with reduced side effects. Molecular docking studies on CSEs 5 and 9 attributed the high inhibition of these compounds to multiple π-π interactions and favorable projection of the cinnamoyl moieties (especially O-3 cinnamoyl) in the enzyme pockets. This work proposes CSEs as new AGIs with potentially reduced side effects.
- Published
- 2021
- Full Text
- View/download PDF